Comorbidity of gastroenterological and cardiovascular pathology as a problem of clinical practice
https://doi.org/10.31146/16828658-ecg-199-3-107-114
Abstract
The purpose of the review: to summarize the information available in the literature and to present to the practitioner information on the relationship of diseases of the gastrointestinal tract with cardiovascular pathology.
Basic provisions. The comorbidity of diseases of the gastrointestinal tract and cardiovascular pathology (CVP) is due to similar risk factors and pathogenetic mechanisms. The results of scientifi c studies of patients with gastrointestinal tract pathology indicate higher cardiac risks and the incidence of CVP in comparison with the general population.
Conclusion. Gastrointestinal disorders can act as risk factors, links in pathogenesis, elements of the clinical picture of CVP. A multidisciplinary approach is needed in the treatment of patients with chronic gastrointestinal pathology in order to best address the underlying problems and existing cardiovascular diseases in this category.
About the Authors
A. Yu. Ryabova
Saratov State Medical University n. a. V.I. Razumovsky
Russian Federation
Russian Federation
Anna Yu. Ryabova - Professor of the Department of Therapy, Gastroenterology and Pulmonology; assistant professor; Doctor of Medical Sciences; Scopus Author ID: 57213286335.
410012, Bolshaya Kazachyia St., 112, Saratov
I. V. Kozlova
Saratov State Medical University n. a. V.I. Razumovsky
Russian Federation
Russian Federation
Irina V. Kozlova - Doctor of Medical Sciences, Professor, Head of the Department of Therapy, Gastroenterology and Pulmonology; Scopus Author ID: 7102626490.
410012, Bolshaya Kazachyia St., 112, Saratov
T. G. Shapovalova
Saratov State Medical University n. a. V.I. Razumovsky
Russian Federation
Russian Federation
Tatyana G. Shapovalova - Professor of the Department of Therapy, Gastroenterology and Pulmonology; Professor; Doctor of Medical Sciences, Scopus Author ID: 6603614978.
410012, Bolshaya Kazachyia St., 112, Saratov
M. M. Shashina
Saratov State Medical University n. a. V.I. Razumovsky
Russian Federation
Russian Federation
Marina M. Shashina - Associate Professor of the Department of Therapy, Gastroenterology and Pulmonology; assistant professor; Candidate of Medical Sciences.
410012, Bolshaya Kazachyia St., 112, Saratov
References
1. Oganov R. G., Simanenkov V. I., Bakulin I. G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5–66. (In Russ.) doi:10.15829/1728–8800–2019–1–5–66
2. Martins J.C.S., Mendes L. S.C., Duraes A. R. Cardiovascular Complications of Gastrointestinal Diseases. J Gastrointest Dig Syst. 2015;5:351. doi:10.4172/2161–069X.1000351
3. Gesualdo M., Scicchitano P., Carbonara S., et al. Th e association between cardiac and gastrointestinal disorders: causal or casual link? J Cardiovasc Med (Hagerstown). 2016 May;17(5):330–8. doi: 10.2459/JCM.0000000000000351. PMID: 26702598.
4. Simanenkov V.I., Maev I. V., Tkacheva O. N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Th erapy and Prevention. 2021;20(1):2758. (in Russ) doi:10.15829/1728–8800–2021–2758
5. Issac T. T., Dokainish H., Lakkis N. M. Role of infl ammation in initiation and perpetuation of atrial fi brillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50: 2021–2028.
6. Mohamed A., Ochoa Crespo D., Kaur G., et al. Gastroesophageal Reflux and Its Association With Atrial Fibrillation: A Traditional Review. Cureus. 2020, September 11;12(9): e10387. doi:10.7759/cureus.10387
7. Maruyama T., Fukata M., Akashi K. Association of atrial fi brillation and gastroesophageal refl ux disease: natural and therapeutic linkage of the two common diseases. J Arrhythm. 2018, 35:43–51. 10.1002/joa3.12125
8. Shavkuta G. V., Cherkasov M. F., Pakhomova V. M., et al. Stomach in the chest or what we know about giant hiatal hernias. South Russian Journal of Th erapeutic Practice. 2021;2(1):115–120. (In Russ.) doi:10.21886/2712–8156–2021–2–1–115–120
9. Xu L., Zhang Y., Xie J., Liu Y., Xu L. Association between gastroesophageal refl ux disease and atrial fi brillation: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2019; 111:874–9. doi:10.17235/reed.2019.5389/2017
10. Jeremic N., Petkovic A., Srejovic I., et al. Eff ects of ischemia and omeprazole preconditioning on functional recovery of isolated rat heart. Rev Bras Cir Cardiovasc. 2015, 30:266–275. doi:10.5935/1678–9741.20150020
11. Ivashkin V. T., Mayev I. V., Sheptulin A. A., et al. Diagno sis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.) doi:10.22416/1382–4376–2017-27-1–50–61
12. Saeed M., Bhandohal J. S., Visco F., Pekler G., Mushiyev S. Gastrocardiac syndrome: a forgotten entity. Am J Emerg Med. 2018; 36:1525. doi:10.1016/j.ajem.2018.05.002
13. Qureshi K., Naeem N., Saleem S., et al. Recurrent Episodes of Paroxysmal Supraventricular Tachycardia Triggered by Dyspepsia: A Rare Case of Gastrocardiac Syndrome. Cureus. 2021;13(9): e17966. Published 2021 Sep 14. doi:10.7759/cureus.17966
14. Chmiela M., Gajewski A., Rudnicka K. Helicobacter pylori vs coronary heart disease – searching for connections. World J Cardiol. 2015;7(4):187-203. doi:10.4330/wjc.v7.i4.187
15. Moroz E. V., Karateev A. E., Kryukov E. V., Cher netsov V. A. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-P rakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):675–684. (In Russ.) doi: 10.14412/1995–4484–2017-675–684
16. Simonova Zh.G., Martusevich A. K., Tarlovskaya E. I. Clinical and pathogenetic aspects of the course of coronary heart disease in combination with peptic ulcer. Th erapeutic archive; 2014;(1): 33–36. (in Russ.)
17. Buzás G. M. Metabolic consequences of Helicobacter pylori infection and eradication. World J Gastroenterol. 2014;20(18):5226–5234. doi:10.3748/wjg.v20.i18.5226
18. V Lee M., Baek H., Park J. S., et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-s ectional study. PLoS One. 2018;13(3): e0193646. Published 2018 Mar 2. doi:10.1371/journal.pone.0193646
19. Kountouras J., Polyzos S. A., Katsinelos P., et al. Cardio- cerebrovascular disease and Helicobacter pylori-r elated metabolic syndrome: We consider eradication therapy as a potential cardio-c erebrovascular prevention strategy. Int J Cardiol. 2017;229: 17-18. doi: 10.1016/j.ijcard.2016.11.265
20. Zuin M., Rigatelli G., Del Favero G., et al. Coronary artery disease and Helicobacter pylori infection: Should we consider eradication therapy as cardiovascular prevention strategy? Int J Cardiol. 2016;223: 711–712. doi: 10.1016/j.ijcard.2016.08.320
21. Fallah, Soudabeh et al. Helicobacter pylori Infection is a Signifi cant Factor Risk for Hyperhomocysteinemia in the Patients with Coronary Artery Disease. Brazilian Archives of Biology and Technology. 2016; 59: e16150509. doi: 10.1590/1678–4324–2016150509
22. Khlynova O. V., Stepina E. A. Specific Features of Vascular Endothelium in Patients with Severe Forms of Inflammatory Bowel Diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(5):98–104. (In Russ.) doi:10.22416/1382–4376–2018–28–5–98–104
23. Bunu D.M., Timoft e C. E., Ciocoiu M., et al. Cardiovascular Manifestations of Infl ammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies. Gastroenterol Res Pract. 2019 Jan 13;2019:3012509. doi: 10.1155/2019/3012509. PMID: 30733802; PMCID: PMC6348818.
24. Patel R.S., Rohit Reddy S., Llukmani A., et al. Cardiovascular Manifestations in Infl ammatory Bowel Disease: A Systematic Review of the Pathogenesis and Management of Pericarditis. Cureus. 2021 Mar 20;13(3): e14010. doi: 10.7759/cureus.14010. PMID: 33884251; PMCID: PMC8054944.
25. Olpin J.D., Sjoberg B. P., Stilwill S. E., Jensen L. E., Rezvani M., Shaaban A. M. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. Radiographics. 2017 Jul-A ug;37(4):1135–1160. doi: 10.1148/rg.2017160121. Epub 2017 May 26. PMID: 28548906.
26. Castellon X., Bogdanova V. Chronic Inflammatory Diseases and Endothelial Dysfunction. Aging Dis. 2016;7(1):81–89. Published 2016 Jan 2. doi:10.14336/AD.2015.0803
27. Bracamonte-B aran W., Čiháková D. Cardiac autoimmunity: myocarditis. Advances in Experimental Medicine and Biology. 2017;1003:187-221. doi: 10.1007/978–3–319–57613–8_10
28. Efe T. H., Cimen T., Ertem A. G., et al. Atrial electromechanical properties in infl ammatory bowel disease. Echocardiography. 2016;33(9):1309–1316. doi: 10.1111/echo.13261
29. Pattanshetty D. J., Gajulapalli R. D., Anna K., Biyyani R. S. S. Prevalence of QT interval prolongation in infl ammatory bowel disease. Th e Turkish Journal of Gastroenterology. 2016;27(2):136–142. doi: 10.5152/tjg.2015.150349
30. Engel T., Ben- Horin S., Beer-Gabel M. Autonomic dysfunction correlates with clinical and infl ammatory activity in patients with Crohn’s disease. Infl ammatory Bowel Diseases. 2015;21(10):2320–2326. doi: 10.1097/MIB.0000000000000508
31. Koutroumpakis E., Ramos-R ivers C., Regueiro M., et al. Association Between Long- Term Lipid Profi les and Disease Severity in a Large Cohort of Patients with Infl ammatory Bowel Disease. Dig Dis Sci. 2016 Mar;61(3):865–71. doi: 10.1007/s10620–015–3932–1. Epub 2015 Oct 29. PMID: 26514677.
32. Harbord M., Annese V., Vavricka S. R., et al. Th e fi rst European evidence-b ased consensus on extra-i ntestinal manifestations in infl ammatory bowel disease. Journal of Crohn’s and Colitis. 2016;10(3):239–254. doi: 10.1093/ecco-jcc/jjv213
33. Oynotkinova O.S., Nikonov E. L., Demidova T. Y., et al. Changes in the intestinal microbiota as a risk factor for dyslipidemia, atherosclerosis and the role of probiotics in their prevention. Th erapeutic Archive. 2020; 92 (9): 94–101. doi: 10.26442/00403660.2020.09.000784
34. Fadeev G.A., Fatykhov R. G., Tsibulkin N. A., Mikhoparova O. Yu., Oschepkova O. B., Abdrak hmanova A. I. Inflammatory mechanisms in genesis of atherosclerosis. Th e Bulletin of Contemporary Clinical Medicine. 2020; 13 (6): 62–67. (in Russ.) doi: 10.20969/VSKM.2020.13(6).62–67
35. Mafune A., Iwamoto T., Tsutsumi Y., et al. Associations among serum trimethylamine-N -oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clin Exp Nephrol. 2016 Oct;20(5):731–739. doi: 10.1007/s10157-015–1207-y
36. Owczarek D., Cibor D., Głowacki M. K., Rodacki T., Mach T. Infl ammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol. 2014;20(1):53–63. doi:10.3748/wjg.v20.i1.53
37. Landman C., Nahon S., Cosnes J., et al. Portomesenteric vein thrombosis in patients with infl ammatory bowel disease. Inflamm Bowel Dis. 2013;19(3):582–589. doi:10.1097/MIB.0b013e31827eea5f
38. Daub S., Lutgens E., Münzel T., Daiber A. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-Th e Pros and Cons for Cardioprotection. Int J Mol Sci. 2020;21(22):8533. Published 2020 Nov 12. doi:10.3390/ijms21228533
39. Ganguly P., Alam S. F. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6. doi:10.1186/1475–2891–14–6
40. Aarestrup J., Jess T., Kobylecki C. J., Nordestgaard B. G., Allin K. H. Cardiovascular Risk Profi le Among Patients With Infl ammatory Bowel Disease: A Population-b ased Study of More Th an 100 000 Individuals. J Crohns Colitis. 2019 Mar 26;13(3):319–323. doi: 10.1093/ecco-jcc/jjy164
41. Chavez L., Mayrovitz H. N. Assessing the Impact of Helicobacter pylori Infection and Infl ammatory Bowel Disease on Pulse Wave Velocity and Arterial Stiff ness. Cureus. 2021;13(5): e14944. doi:10.7759/cureus.14944
42. Fomina E. S., Nikiforov V. S. Arterial Stiffness and Vascular Aging: Eff ects of Hypertension. Th e Russian Archives of Internal Medicine. 2021;11(3):196–202. (in Russ.) doi:10.20514/2226–6704–2021–11–3–196–202
43. Cappello M., Licata A., Calvaruso V., et al. Increased expression of markers of early atherosclerosis in patients with infl ammatory bowel disease. Eur J Intern Med. 2017 Jan;37:83–89. doi: 10.1016/j.ejim.2016.10.004
44. Biondi R.B., Salmazo P. S., Bazan S. G.Z., Hueb J. C., de Paiva S. A.R., Sassaki L. Y. Cardiovascular Risk in Individuals with Infl ammatory Bowel Disease. Clin Exp Gastroenterol. 2020;13:107-113. Published 2020 Apr 24. doi:10.2147/CEG.S243478
45. Patel V. B., Why H. J., Richardson P. J., Preedy V. R. Th e eff ects of alcohol on the heart. Adverse Drug React Toxicol Rev. 1997 Mar;16(1):15–43.
46. Chayanupatkul M., Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014;8(3):308–315. doi:10.1007/s12072–014–9531-y
47. Carvalho M. V.H., Kroll P. C., Kroll R. T.M., Carvalho V. N. Cirrhotic cardiomyopathy: the liver affects the heart. Braz J Med Biol Res. 2019;52(2): e7809. doi:10.1590/1414–431X20187809
48. Ruiz-del-Á rbol L., Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015;21(41):11502–11521. doi:10.3748/wjg.v21.i41.11502
49. Naqvi I. H., Mahmood K., Naeem M., Vashwani A. S., Ziaullah S. Th e heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. Prz Gastroenterol. 2016;11(4):247-256. doi:10.5114/pg.2016.57962
50. Batchvarov V., Camm A. J., Gersh B. J., Downey B. C. QT dispersion: Measurement and interpretation. 2018. Available at: http://www.uptodate.com (Access on 2020 April 17)
51. Mozos I. Arrytmia risk in liver cirrhosis. World J Hepatol. 2015;7(4):662–672. doi:10.4254/wjh.v7.i4.662
52. Silvestre O., Farias A. Q., Ramos D., Furtado M. S., Rodrigues A., Ximenes R. O., et al. B-blocker therapy for cirrhotic cardiomyopathy: a ramdomised- controled trial. Eur J Gastroenterol Hepatol. 2018;30(8):930–937. doi:10.1097/MEG.0000000000001128
53. Arslan U., Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases. 2020 Oct 26;8(20):4688–4699. doi: 10.12998/wjcc.v8.i20.4688
54. Wong V.W-S., Wong G. L., Yeung J. C., Fung C. Y., Chan J. K., Chang Z. H., et al. Long-term clinical outcomes aft er fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016;63(3):754–763. doi:10.1002/hep.28253
55. Ma J., Hwang S. J., Pedley A., Massaro J. M., Hoff mann U., Chung R. T., et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390–397. doi:10.1016/j.jhep.2016.09.022
56. Wu S., Wu F., Ding Y., Hou J., Bi J., Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. Published 2016 Sep 16. doi:10.1038/srep33386
57. Targher G., Byrne C. D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of in cident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600. doi:10.1016/j.jhep.2016.05.013
58. Wild S. H., Walker J. J., Morling J. R., et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41(2):341–347. doi:10.2337/dc17-1590
59. Lazebnik L. B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4– 52. (In Russ.) doi: 10.31146/1682–8658-ecg-185–1–4–52
60. Trukhan D. I., Degovtsov E. N., Davydov E. L. Cholec ystocardial syndrome in real clinical practice. Meditsinskiy sovet = Medical Council. 2021;(4):212–219. (In Russ.) doi:10.21518/2079–701X-2021–4–212–219
61. Ryabova A. Yu., Shapovalova T. G., Shashina M. M., et al. Acute cholecystitis disguised as acute myocardial infarction. Eksp Klin Gastroenterol. 2016;(2):68–70. (In Russ.)
62. Oganezova I.A., Egorova S. V., Skvortsova T. E., Med vedeva O. I. Сholecistocardiac syndrome: troubles of differential diagnosis. Experimental and Clinical Gastroenterology. 2018;(2):110–114. (In Russ.)
63. Chevli P.A., Freedman B. I., Hsu F. C., et al. Plasma metabolomic profi ling in subclinical atherosclerosis: the Diabetes Heart Study. Cardiovasc Diabetol. 2021 Dec 7;20(1):231. doi: 10.1186/s12933–021–01419-y
64. Li W., Shu S., Cheng L., Hao X., Wang L., Wu Y., Yuan Z., Zhou J. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions. Atherosclerosis. 2020 Jan;292:193–200. doi: 10.1016/j.atherosclerosis.2019.11.026
Review
For citations:
Ryabova A.Yu., Kozlova I.V., Shapovalova T.G., Shashina M.M. Comorbidity of gastroenterological and cardiovascular pathology as a problem of clinical practice. Experimental and Clinical Gastroenterology. 2022;(3):107-114. (In Russ.) https://doi.org/10.31146/16828658-ecg-199-3-107-114
Views:
368
Email this article 